Funded Startups in Emeryville
Across these 35 Emeryville entries (round dates from 2020-03-17 through 2025-10-01), one disclosed deal stands out: Amyris’ $400M post-IPO debt round on 20…
Across these 35 Emeryville entries (round dates from 2020-03-17 through 2025-10-01), one disclosed deal stands out: Amyris’ $400M post-IPO debt round on 2021-11-08, which is far above the next-largest disclosed amounts (e.g., Zymergen at $300M on 2020-09-08 and Lucira Health at $80M on 2022-02-04). The list also shows clustering in both time and sector: Biotechnology appears repeatedly (e.g., Ansa Biotechnologies $45M in 2025-10-01, Ayar Labs $155M in 2024-12-11, Nutcracker Therapeutics $167M in 2022-03-14, and 4D Molecular Therapeutics $120M in 2023-05-04), with multiple rounds concentrated in 2024 across several biotech names (Eko Health $41M on 2024-06-05; Gritstone Bio $33M on 2024-04-01; Geltor is also present but undisclosed at 2025-08-07). Amount disclosures span from $3M (Injectsense on 2023-11-15) up to $400M, while some rounds provide no figure ($undisclosed appears for Geltor in 2025-08-07, Mindful Schools in 2023-12-15, Finless Foods in 2022-11-23, MycoWorks in 2022-10-18), indicating meaningful pricing opacity in certain deals.
Most recent rounds
35 shownRelated listings
Frequently asked
Which Emeryville deal is the size outlier, and how separated is it from the rest of the disclosed amounts?
Amyris’ $400M post-IPO debt round on 2021-11-08 dwarfs the next-largest disclosed amounts in this set, including Zymergen’s $300M on 2020-09-08 and Lucira Health’s $80M on 2022-02-04.
How concentrated are rounds in the most recent portion of the timeline shown?
The dataset runs from 2020-03-17 to 2025-10-01, and the most recent entries cluster in 2025–2024: for example, Oxide Computer Company is $69M on 2025-07-16 and Ansa Biotechnologies is $45M on 2025-10-01, while 2024 includes multiple sizable rounds such as Ayar Labs $155M (2024-12-11), Eko Health $41M (2024-06-05), and Gritstone Bio $33M (2024-04-01).
Which sectors are over-represented, and does the concentration change by time window?
Biotechnology is the most frequent repeated sector across the page (e.g., Ansa Biotechnologies 2025-10-01 $45M; Eko Health 2024-06-05 $41M; 4D Molecular Therapeutics 2023-05-04 $120M; Nutcracker Therapeutics 2022-03-14 $167M), while other categories appear less consistently.
What fraction of entries have missing or non-disclosed round amounts, and where do they appear?
Four of the 35 rows are marked undisclosed: Geltor (2025-08-07), Mindful Schools (2023-12-15), Finless Foods (2022-11-23), and MycoWorks (2022-10-18), so undisclosed figures are concentrated in specific deal announcements rather than spreading across every year.
Are there notable stage-label patterns among the disclosed rounds?
Several large rounds sit in later-stage labels, including Ayar Labs’ Series D $155M (2024-12-11), Nutcracker Therapeutics’ Series C $167M (2022-03-14), and Ansa Biotechnologies’ Series B $45M (2025-10-01), while multiple entries use Series Unknown (e.g., Oxide Computer Company $69M on 2025-07-16 and Sepion Technologies $18M on 2024-10-03).
What’s the smallest disclosed round, and does any smaller disclosed amount align with a different sector than the dominant biotech pattern?
The smallest disclosed amount is $3M for Injectsense on 2023-11-15, and it is also labeled Biotechnology; in contrast, the most extreme high end is driven by non-overlapping post-IPO/debt scale rounds like Amyris $400M (2021-11-08) and Zymergen $300M (2020-09-08).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.